Numeric Investors LLC grew its stake in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) by 16.2% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 60,200 shares of the biotechnology company’s stock after purchasing an additional 8,400 shares during the period. Numeric Investors LLC owned approximately 0.27% of Concert Pharmaceuticals worth $840,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds also recently bought and sold shares of CNCE. Citadel Advisors LLC purchased a new stake in shares of Concert Pharmaceuticals in the second quarter valued at approximately $6,634,000. Driehaus Capital Management LLC purchased a new stake in shares of Concert Pharmaceuticals in the first quarter valued at approximately $7,353,000. Lyon Street Capital LLC purchased a new stake in shares of Concert Pharmaceuticals in the first quarter valued at approximately $1,467,000. Vanguard Group Inc. grew its position in shares of Concert Pharmaceuticals by 11.0% in the second quarter. Vanguard Group Inc. now owns 756,513 shares of the biotechnology company’s stock valued at $10,553,000 after purchasing an additional 74,801 shares in the last quarter. Finally, Paulson & CO. Inc. purchased a new stake in shares of Concert Pharmaceuticals in the first quarter valued at approximately $1,198,000. Institutional investors and hedge funds own 61.62% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This news story was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://stocknewstimes.com/2017/10/13/numeric-investors-llc-has-840000-stake-in-concert-pharmaceuticals-inc-cnce.html.
Shares of Concert Pharmaceuticals, Inc. (CNCE) opened at 14.91 on Friday. The firm’s market capitalization is $338.26 million. Concert Pharmaceuticals, Inc. has a 52 week low of $7.11 and a 52 week high of $19.11. The stock has a 50 day moving average price of $14.92 and a 200 day moving average price of $14.75.
Concert Pharmaceuticals (NASDAQ:CNCE) last issued its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.58) EPS for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.04. Concert Pharmaceuticals had a negative net margin of 60,681.70% and a negative return on equity of 61.98%. The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.20 million. Equities analysts forecast that Concert Pharmaceuticals, Inc. will post ($2.18) earnings per share for the current fiscal year.
In other Concert Pharmaceuticals news, insider Ryan Lynch sold 3,500 shares of the business’s stock in a transaction on Thursday, September 14th. The shares were sold at an average price of $14.51, for a total value of $50,785.00. Following the transaction, the insider now owns 9,500 shares in the company, valued at approximately $137,845. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 10.10% of the company’s stock.
A number of research analysts recently commented on CNCE shares. Zacks Investment Research cut Concert Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Concert Pharmaceuticals in a report on Monday, September 18th. ValuEngine upgraded Concert Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Finally, BidaskClub cut Concert Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, August 4th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company’s stock. Concert Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $24.60.
Concert Pharmaceuticals Profile
Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.
Receive News & Ratings for Concert Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.